IMR Press / RCM / Volume 9 / Issue 3 / pii/1560999979771-795651629

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Nesiritide in Acute Decompensated Heart Failure: Current Status and Future Perspectives
Show Less
1 Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
2020 Division of Cardiovascular Diseases, 2nd Department of Internal Medicine, General University Hospital, 1st School of Medicine, Charles University, Prague, Czech Republic
Rev. Cardiovasc. Med. 2008, 9(3), 151–158;
Published: 30 September 2008
Acute decompensated heart failure (ADHF) is a growing public health problem with high mortality and costs. ADHF often, if not usually, occurs in the setting of cardiovascular and noncardiovascular comorbidities as well as advanced age. New insights provide support for the concept of heart failure as a state of deficiency of and/or resistance to endogenous B-type natriuretic peptide. The primary goals of ADHF therapy are to relieve symptoms and optimize volume status with minimal side effects. Few therapies are proven to effectively do so. Nesiritide is a balanced vasodilator with favorable neurohumoral effects and is superior to placebo in providing rapid symptom relief and to nitroglycerin in reducing filling pressures. Recent trials confirm a lack of renal toxicity at recommended doses. An adequately powered multinational mortality trial is underway. Nesiritide represents a proven therapy for normotensive/hypertensive ADHF patients with severe symptoms at rest.
Acute decompensated heart failure
B-type natriuretic peptide
Renal function
Back to top